These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29439729)

  • 1. Application of Neural Networks for classification of Patau, Edwards, Down, Turner and Klinefelter Syndrome based on first trimester maternal serum screening data, ultrasonographic findings and patient demographics.
    Catic A; Gurbeta L; Kurtovic-Kozaric A; Mehmedbasic S; Badnjevic A
    BMC Med Genomics; 2018 Feb; 11(1):19. PubMed ID: 29439729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Only a minority of sex chromosome abnormalities are detected by a national prenatal screening program for Down syndrome.
    Viuff MH; Stochholm K; Uldbjerg N; Nielsen BB; ; Gravholt CH
    Hum Reprod; 2015 Oct; 30(10):2419-26. PubMed ID: 26251461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.
    Karadzov-Orlic N; Egic A; Milovanovic Z; Marinkovic M; Damnjanovic-Pazin B; Lukic R; Joksic I; Curkovic A; Mikovic Z
    Prenat Diagn; 2012 Jul; 32(7):638-43. PubMed ID: 22570267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First trimester combined test for Down syndrome screening in unselected pregnancies - a report of a 13-year experience.
    Lee FK; Chen LC; Cheong ML; Chou CY; Tsai MS
    Taiwan J Obstet Gynecol; 2013 Dec; 52(4):523-6. PubMed ID: 24411037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Performance of different methods of estimating risk screening for chromosomal anomalies].
    Avătăjitei MC; Moscalu M; Martiniuc V; Onofriescu M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):515-22. PubMed ID: 23077946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-trimester screening for trisomies 18 and 13, triploidy and Turner syndrome by detailed early anomaly scan.
    Wagner P; Sonek J; Hoopmann M; Abele H; Kagan KO
    Ultrasound Obstet Gynecol; 2016 Oct; 48(4):446-451. PubMed ID: 26611869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
    Audibert F; Gagnon A; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
    Kagan KO; Valencia C; Livanos P; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jan; 33(1):18-22. PubMed ID: 19031473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory.
    Petersen AK; Cheung SW; Smith JL; Bi W; Ward PA; Peacock S; Braxton A; Van Den Veyver IB; Breman AM
    Am J Obstet Gynecol; 2017 Dec; 217(6):691.e1-691.e6. PubMed ID: 29032050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.